Media Coverage

Quest Diagnostics announced this week that it is participating in the NCI-Molecular Analysis for Therapy Choice clinical trial as a designated laboratory. The firm said both its Med Fusion 50Seq cancer panel and IBM Watson Genomics from Quest Diagnostics service fulfill the trial's criteria for tumor profiling. Under the terms of the collaboration, when oncologists at participating NCI-MATCH sites order tumor profiling to guide clinical care for their patients, Quest will look for trial matches for the patients.

Blockchain holds much promise for improving data privacy, integrity, and quality, although a lot of companies are taking a wait-and-see approach to the model. Quest Diagnostics is not one of them. The provider of clinical lab services for more than a year has been involved in pilot project with other healthcare companies to apply blockchain technology to improve data quality and reduce administrative costs associated with changes to healthcare provider demographic data.

When you have an illness, you begin to learn a whole new language when it comes to taking responsibility for your health. Your physical triggers like (cardiovascular disease, high blood pressure, leaky gut, IBS, TSH, fibromyalgia, Type II Diabetes, hypothyroidism, dementia, autism, Parkinson’s, bipolar, autism, schizophrenia, colon, rectal and breast cancers), take center stage in your search for wellness. If you’re not sure if you have MTHFR Gene Mutation, but you have symptoms, you can order the test through your doctor. Most insurance will cover some of the expense. Other options will require you to create a user login: MTHFR Support, dnalife Spectracell Labs, Quest Diagnostics and Lab Corp.

Quest Diagnostics (DGX), a leading provider of diagnostic information services, today announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, the largest precision medicine trial of its kind. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Tumor gene testing by a designated lab is the only pathway for patients to enroll.

Sonora Quest Laboratories, Arizona’s leading provider of diagnostic information services, is pleased to welcome Sonya Engle as Chief Operations Officer. An executive with extensive experience leading laboratory testing, program expansion and strategic relationship management initiatives, Engle will head Sonora Quest's laboratory and technical operations.[CR-LF][CR-LF]As COO, Engle will combine operations and talent development, while focusing on motivating and leading a high-performance team to accommodate the rapid growth, services, and innovation at Sonora Quest.

Rejenevie™ Therapeutics announced the commencement of the company's Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration treatments targeting age-related diseases.[CR-LF]Upon arrival at the Okyanos Center, the restored stem cells are delivered back into the patient through intravenous infusion in a process lasting approximately one hour. After the patient is discharged and returns home, he or she receives periodic blood testing over a 12-month period using a kit developed with global diagnostics company Quest Diagnostics to ensure safety and to determine the therapy's effectiveness.

Quest Diagnostics, a leading provider of diagnostic information services, today announced it is participating as a designated laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial, the largest precision medicine trial of its kind. The trial is co-led by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Tumor gene testing by a designated lab is the only pathway for patients to enroll.

Nonfasting and fasting lipid levels from the same patients had similar results for associations with incident coronary and atherosclerotic cardiovascular disease, according to results published in JAMA Internal Medicine. Mora reports receiving grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute and Pfizer during the conduct of the study; personal fees from Amgen, Pfizer, and Quest Diagnostics, and grants from Atherotech Diagnostics Lab outside the submitted work. Please see study for all other authors’ relevant financial disclosures.

UnitedHealthcare, the health insurance arm of UnitedHealth Group, has once again been named the most valuable healthcare brand in the world by Brand Finance, a business valuation and strategy consultancy.[CR-LF][CR-LF]Each year, Brand Finance uses a seven-step process to assess and rank the value of thousands of companies' brands from around the world. Brand Finance uses a variety of metrics, including marketing investment and business performance, to evaluate brands to determine their strength. Access additional information about the brand valuation methodology here. Quest Diagnostics appeared at number 25.

The rate of workforce drug positivity hit a fourteen-year high in 2018, according to a new analysis released by Quest Diagnostics, a provider of diagnostic information services. Positivity rates in the combined U.S. workforce increased nearly 5% in urine drug tests (4.2% in 2017 versus 4.4% in 2018), climbing to the highest level since 2004 (4.5%) and are now more than 25 % higher than the thirty-year low of 3.5% recorded between 2010 and 2012.